Solid Biosciences is trading at $8.34 in pre-market, down 6.49%, with the catalyst unconfirmed. - No verified company-specific announcement, earnings release, FDA update, or clinical-trial news was identified for September 23, 2026; the investor-relations page lists no releases dated September 22 or 23. - Biotech-sector strength and mostly flat major indexes do not clearly explain the isolated decline; follow-up is warranted for delayed news or trading-specific factors.